Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Exanthema × Erlotinib Hydrochloride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 150 Lung Neoplasms 58 Pancreatic Neoplasms 34 Neoplasms 20 Neoplasm Metastasis 15 Breast Neoplasms 15 Adenocarcinoma of Lung 15 Brain Neoplasms 14 Adenocarcinoma, Bronchiolo-Alveolar 13 Glioblastoma 12 Non-Squamous Non-Small Cell Lung Cancer 11 Gliosarcoma 11 Squamous Cell Carcinoma of Head and Neck 10 Head and Neck Neoplasms 10 Carcinoma, Hepatocellular 10 Colorectal Neoplasms 8 Carcinoma, Renal Cell 8 Esophageal Neoplasms 6 Urinary Bladder Neoplasms 5 Gallbladder Neoplasms 5 Colonic Neoplasms 5 Central Nervous System Neoplasms 5 Carcinoma, Squamous Cell 5 Adenocarcinoma 5 Rectal Neoplasms 4 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Liver Neoplasms 4 Kidney Neoplasms 4 Fallopian Tube Neoplasms 4

Interventions

Fulvestrant 2 ruxolitinib 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Triamcinolone Acetonide 1 Tetracycline 1 Sirolimus 1 Prednisone 1 Panitumumab 1 Minocycline 1 Loperamide 1 Irinotecan 1 IFL protocol 1 Hydrocortisone 1 Gels 1 Erlotinib Hydrochloride 1 Doxycycline 1 Dapsone 1 Clindamycin 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡